FDA Approves ARGATROBAN — Accord Healthcare Inc.

# FDA Approves Accord Healthcare's Argatroban Injectable, Expanding Anticoagulant Market Accord Healthcare Inc. received FDA approval for its intravenous argatroban formulation (NDA212035) on June 7, 2021, strengthening the company's position in the critical care anticoagulant market and potentially offering healthcare providers an additional option for heparin-induced thrombocytopenia treatment. The approval could enable Accord to capture greater market share in the specialty injectable segment, though it enters a competitive landscape with established argatroban suppliers.